Safety of early discharge for low-risk patients with febrile neutropenia: A multicenter randomized controlled trial

Journal of Clinical Oncology

Volumn 29, Issue 30, 2011, Pages 3977-3983

  Talcott, James A ^a,b   Yeap, Beow Y ^a   Clark, Jack A ^c,d   Siegel, Robert D ^e   Loggers, Elizabeth Trice ^f   Lu, Charles ^g   Godley, Paul A ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Helen and Harry Gray Cancer Center   (United States)

^f GROUP HEALTH RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZTREONAM; CEFTAZIDIME; CEPHALOSPORIN; CREATININE; HEMOPOIETIC GROWTH FACTOR; IMIPENEM; PENICILLIN G; VANCOMYCIN;

ACUTE LEUKEMIA; ADULT; AGED; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EARLY DISCHARGE; FEBRILE NEUTROPENIA; FEMALE; FLUID INTAKE; FOLLOW UP; HOME CARE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPOTENSION; LOW RISK PATIENT; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PATIENT DISCHARGE; RISK FACTORS; YOUNG ADULT;

EID: 80054736109     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.0884     Document Type: Article

References (35)

1. Stokes ME, Muehlenbein CE, Marciniak MD, et al.: Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 15:669-682, 2009
2. Schimpff S, Satterlee W, Young VM, et al.: Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284:1061-1065, 1971
3. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332, 1993
4. Talcott JA, Finberg R, Mayer RJ, et al.: The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561-2568, 1988 (Pubitemid 19048173)
5. Talcott JA, Siegel RD, Finberg R, et al.: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
6. Klastersky J, Paesmans M, Rubenstein EB, et al.: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051, 2000 (Pubitemid 30644129)
7. Talcott JA, Whalen A, Clark J, et al.: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107-114, 1994 (Pubitemid 24020628)
8. Rubenstein EB, Rolston K, Benjamin RS, et al.: Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640-3646, 1993 (Pubitemid 23152677)
9. Escalante CP, Rubenstein EB, Rolston KV: Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Invest 15:237-242, 1997 (Pubitemid 27261664)
10. Rubenstein EB, Rolston K: Outpatient management of febrile episodes in neutropenic cancer patients. Support Care Cancer 2:369-373, 1994
11. Klastersky J, Paesmans M, Georgala A, et al.: Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129-4134, 2006 (Pubitemid 46622289)
12. Innes H, Lim SL, Hall A, et al.: Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: Feasibility and safety in routine clinical practice. Support Care Cancer 16:485-491, 2008 (Pubitemid 351502757)
13. Bash RO, Katz JA, Cash JV, et al.: Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74:189-196, 1994 (Pubitemid 24187629)
14. Gardembas-Pain M, Desablens B, Sensebe L, et al.: Home treatment of febrile neutropenia: An empirical oral antibiotic regimen. Ann Oncol 2:485-487, 1991
15. Mullen CA, Buchanan GR: Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient. J Clin Oncol 8:1998-2004, 1990
16. Elting LS, Lu C, Escalante CP, et al.: Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606-611, 2008 (Pubitemid 351264355)
17. Freifeld A, Sankaranarayanan J, Ullrich F, et al.: Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 16:181-191, 2008
18. Pizzo PA, Hathorn JW, Hiemenz J, et al.: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552- 558, 1986
19. Kern WV, Cometta A, De Bock R, et al.: Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy: International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341:312-318, 1999 (Pubitemid 29350301)
20. Freifeld A, Marchigiani D, Walsh T, et al.: A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305-311, 1999
21. Finberg RW, Talcott JA: Fever and neutropenia: How to use a new treatment strategy. N Engl J Med 341:362-363, 1999
22. Marti FM, Cullen MH, Roila F, et al.: Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol 20:166-169, 2009 (suppl 4)
23. Malik IA, Khan WA, Karim M, et al.: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 98:224-231, 1995
24. Hidalgo M, Hornedo J, Lumbreras C, et al.: Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial. Cancer 85:213-219, 1999 (Pubitemid 29031377)
25. Innes HE, Smith DB, O'Reilly SM, et al.: Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: A prospective randomised controlled single centre study. Br J Cancer 89:43-49, 2003 (Pubitemid 36897933)
26. Gupta A, Swaroop C, Agarwala S, et al.: Randomized controlled trial comparing oral amoxicillinclavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric lowrisk febrile neutropenia. J Pediatr Hematol Oncol 31:635-641, 2009
27. Feld R, Paesmans M, Freifeld AG, et al.: Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of the Immunocompromised Host Society/ Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 35:1463-1468, 2002 (Pubitemid 36020688)
28. Talcott JA: Outpatient management of febrile neutropenia: Should we change the standard of care? Oncologist 2:365-373, 1997
29. Aaronson NK, Ahmedzai S, Bergman B, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993 (Pubitemid 23073154)
30. Fazio AF: A concurrent validational study of the NCHS General Well-Being Schedule. Vital Health Stat 2 73:1-53, 1977
31. Poston WS 2nd, Olvera NE, Yanez C, et al.: Evaluation of the factor structure and psychometric characteristics of the General Well-Being Schedule (GWB) with Mexican American women. Women Health 27:51-64, 1998 (Pubitemid 28404540)
32. Himmelfarb S, Murrell SA: Reliability and validity of five mental health scales in older persons. J Gerontol 38:333-339, 1983 (Pubitemid 13083968)
33. Costa PT Jr, McCrae RR: Cross-sectional studies of personality in a national sample: 1. Development and validation of survey measures. Psychol Aging 1:140-143, 1986
34. Davies AR, Ware JE: GHAA's Consumer Satisfaction Survey and User's Manual. Washington, DC, Group Health Association of America, 1991
35. Hendricks AM, Loggers ET, Talcott JA: Costs of home versus inpatient treatment for fever and neutropenia: Analysis of a multicenter randomized trial. J Clin Oncol 29:3984-3989, 2011